Abstract：
Immunotherapy and in particular programmed cell death protein 1 (PD-1) inhibitors have been applied not only in the management of recurrent or metastatic disease but also as component of potentially curative treatment for many solid tumors. The incorporation of immunotherapy as neoadjuvant and /or adjuvant therapy in the treatment paradigm of locally advanced squamous cell carcinoma of the head and neck (SCCHN) is appealing with the goals of enhancing antitumor efficacy and, at the same time, reduce toxicity. This review analyzes the rationale for employing immunotherapy in the neoadjuvant and adjuvant settings, reviews the results of relevant clinical trials, and examines the potential benefits and caveats of neoadjuvant and/or adjuvant approaches in patients with SCCHN.
摘要：
免疫疗法，特别是程序性细胞死亡蛋白1（PD-1）抑制剂不仅已用于治疗复发性或转移性疾病，而且还作为许多实体瘤的潜在治愈性治疗的组成部分。在局部晚期头颈部鳞状细胞癌（SCCHN）的治疗范例中，将免疫疗法作为新辅助和/或辅助疗法的结合具有吸引力，旨在增强抗肿瘤功效，同时,降低毒性。这篇综述分析了在新辅助和辅助环境中采用免疫疗法的基本原理。回顾相关临床试验的结果，并检查了新辅助和/或辅助方法在SCCHN患者中的潜在益处和注意事项。
